A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D6)

Psychotherapy and Psychosomatics

Volumn 86, Issue 3, 2017, Pages 141-149

  Timmerby, N ^a   Andersen, J H ^a   Sondergaard S ^a   Ostergaard S D ^b,c   Bech, Per ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

6 Item Hamilton Depression Rating Scale; Antidepressant medication; Clinimetrics; Depression rating scale; Systematic literature review

Indexed keywords

CITALOPRAM; DESVENLAFAXINE; DULOXETINE; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE;

17 ITEM HAMILTON DEPRESSION RATING SCALE; 6 ITEM HAMILTON DEPRESSION RATING SCALE; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE SEVERITY; EMBASE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; MEDLINE; META ANALYSIS (TOPIC); MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PSYCINFO; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VALIDITY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; REPRODUCIBILITY; STANDARDS; VALIDATION STUDY;

DEPRESSION; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; VALIDATION STUDIES AS TOPIC;

EID: 85018717576     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000457131     Document Type: Article

References (87)

1. Feinstein AR: T. Duckett Jones Memorial Lecture. The Jones criteria and the challenges of clinimetrics. Circulation 1982; 66: 1-5.
2. Feinstein AR: Clinimetrics. New Haven, Yale University Press, 1987.
3. Feinstein AR: Clinical biostatistics. XII. On exorcising the ghost of Gauss and the curse of Kelvin. Clin Pharmacol Ther 1971; 12: 1003-1016.
4. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
5. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
6. Kendall MG: Factor analysis as a statistical technique. J R Stat Soc Series B 1950; 12: 60-73.
7. Rasch G: Probabilistic Models for Some Intelligence and Attainment Tests. Copenhagen, Danish Institute for Educational Research, 1960.
8. Tomba E, Bech P: Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychother Psychosom 2012; 81: 333-343.
9. Bech P: Clinimetric dilemmas in outcome scales for mental disorders. Psychother Psychosom 2016; 85: 323-326.
10. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG: Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51: 161-170.
11. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A: The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63: 290-299.
12. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
14. Bech P: The responsiveness of the different versions of the Hamilton Depression Scale. World Psychiatry 2015; 14: 309-310.
15. Khan A, Bhat A, Kolts R, Thase ME, Brown W: Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010; 16: 217-226.
16. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E: Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016; 21: 523-530.
17. Bech P, Cialdella P, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefson GD: Metaanalysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression. Br J Psychiatry 2000; 176: 421-428.
18. Licht RW, Qvitzau S, Allerup P, Bech P: Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005; 111: 144-149.
19. Guy W: The Clinical Global Impression Scale; in Guy W (ed): ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, US Department of Health, Education, and Welfare, 1976, pp 218-222.
20. Ruhe HG, Dekker JJ, Peen J, Holman R, de Jonghe F: Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Compr Psychiatry 2005; 46: 417-427.
21. Kyle PR, Lemming OM, Timmerby N, Sondergaard S, Andreasson K, Bech P: The validity of the different versions of the Hamilton Depression Scale in separating remission rates of placebo and antidepressants in clinical trials of major depression. J Clin Psychopharmacol 2016; 35: 453-456.
22. Bobo WV, Anglero GC, Jenkins G, Hall-Flavin DK, Weinshilboum R, Biernacka JM: Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRNAMPS) data. Hum Psychopharmacol 2016; 31: 185-192.
23. Bobes J, Bulbena A, Luque A, Dal-Re R, Ballesteros J, Ibarra N, Bech P: The sufficiency of the HAM-D6 as an outcome instrument in the acute therapy of antidepressants in the outpatient setting. Int J Psychiatry Clin Pract 2007; 11: 146-150.
24. Holmskov J, Licht RW, Andersen K, Stage TB, Nilsson FM, Stage KB, Valentin JB, Bech PB: Diagnostic conversion to bipolar disorder in unipolar depressed patients participating in trials of antidepressants. Eur Psychiatry 2017;40:76-81.
25. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990; 18: 289-299.
26. Martiny K, Refsgaard E, Lund V, Lunde M, Sorensen L, Thougaard B, Lindberg L, Bech P: The day-to-day acute effect of wake therapy in patients with major depression using the HAM-D6 as primary outcome measure: results from a randomised controlled trial. PLoS One 2013; 8:e67264.
27. Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, et al: A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 1994; 32: 105-114.
28. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38: 592-602.
29. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M: Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64: 243-249.
30. Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987; 44: 862-866.
31. Schneider LS, Nelson JC, Clary CM, Newhouse P, Krishnan KR, Shiovitz T, Weihs K; Sertraline Elderly Depression Study Group: An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160: 1277-1285.
32. Feiger AD: A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 1996; 32: 659-665.
33. Wilcox CS, Ferguson JM, Dale JL, Heiser JF: A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32: 335-342.
34. Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 2002; 159: 1361-1366.
35. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA: Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008; 24: 1877-1890.
36. Liebowitz MR, Yeung PP, Entsuah R: A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 2007; 68: 1663-1672.
37. Helmreich I, Wagner S, Mergl R, Allgaier AK, Hautzinger M, Henkel V, Hegerl U, Tadic A: Sensitivity to changes during antidepressant treatment: A comparison of unidimensional subscales of the Inventory of Depressive Symptomatology (IDS-C) and the Hamilton Depression Rating Scale (HAMD) in patients with mild major, minor or subsyndromal depression. Eur Arch Psychiatry Clin Neurosci 2012; 262: 291-304.
38. Martiny K, Lunde M, Unden M, Dam H, Bech P: Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. Acta Psychiatr Scand 2005; 112: 117-125.
39. 6) as outcome measure. J Affect Disord 2016; 190: 842-845.
40. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA: A doubleblind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26: 482-488.
41. Moller HJ, Glaser K, Leverkus F, Gobel C: Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Pharmacopsychiatry 2000; 33: 206-212.
42. Feiger AD, Rickels K, Rynn MA, Zimbroff DL, Robinson DS: Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006; 67: 1354-1361.
43. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ: Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR ∗ D trial. Acta Psychiatr Scand 2012; 125: 342-348.
44. Sondergaard MP, Jarden JO, Martiny K, Andersen G, Bech P: Dose response to adjunctive light therapy in citalopram-treated patients with post-stroke depression. A randomised, double-blind pilot study. Psychother Psychosom 2006; 75: 244-248.
45. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, Krishnan KR, Fernandes S: Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 2011; 31: 727-733.
46. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P: A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003; 44: 216-221.
47. Bech P: Clinical Psychometrics. Oxford, Wiley Blackwell, 2012.
48. Ostergaard SD, Bech P, Trivedi MH, Wisniewski SR, Rush AJ, Fava M: Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). J Affect Disord 2014; 163: 18-24.
49. Thase ME, Ninan PT, Musgnung JJ, Trivedi MH: Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord 2011; 13:pii:PCC.10m00979.
50. Martiny K, Lunde M, Simonsen C, Clemmensen L, Poulsen DL, Solstad K, Bech P: Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand 2004; 109: 230-234.
51. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM; GLYX-13 Clinical Study Group: Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 2015; 21: 140-149.
52. Sheehan DV, Rozova A, Gossen ER, Gibertini M: The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. Psychopharmacol Bull 2009; 42: 5-22.
53. Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, Woo A, Trivedi MH: The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601-611.
54. Bech P, Allerup P, Larsen ER, Csillag C, Licht RW: The Hamilton Depression Scale (HAMD) and the Montgomery-Asberg Depression Scale (MADRS). A psychometric re-analysis of the European genome-based therapeutic drugs for depression study using Rasch analysis. Psychiatry Res 2014; 217: 226-232.
55. Andrich D, Sheridan BE, Luo G: RUMM2030, version 5.1. Perth, RUMM Laboratory Pty Ltd, 2010.
56. van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J: Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10: 3-9.
57. Hooper CL, Bakish D: An examination of the sensitivity of the six-item Hamilton Rating Scale for Depression in a sample of patients suffering from major depressive disorder. J Psychiatry Neurosci 2000; 25: 178-184.
58. Adler M, Hetta J, Isacsson G, Brodin U: An item response theory evaluation of three depression assessment instruments in a clinical sample. BMC Med Res Methodol 2012; 12: 84.
59. Hays RD, Hadorn D: Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res 1992; 1: 73-75.
60. Bech P, Allerup P, Larsen ER, Csillag C, Licht RW: The Hamilton Depression Scale (HAMD) and the Montgomery-Asberg Depression Scale (MADRS). A psychometric re-analysis of the European Genome-Based Therapeutic Drugs for Depression Study using Rasch analysis. Psychiatry Res 2014; 217: 226-232.
61. Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R: Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972; 26: 57-63.
62. Bech P: Measurement-Based Care in Mental Disorders. New York, Springer, 2016.
63. Fried EI, van Borkulo CD, Epskamp S, Schoevers RA, Tuerlinckx F, Borsboom D: Measuring depression over time⋯ Or not? Lack of unidimensionality and longitudinal measurement invariance in four common rating scales of depression. Psychol Assess 2016; 28: 1354-1367.
64. Kramer PD: Ordinarily Well. The Case for Antidepressants. New York, Farrar, Straus and Giroux, 2016.
65. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA: The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 2016; 85: 270-288.
66. Embretson SE: Implications of a multidimensional latent trait model for measuring change; in Collins LM, Horn J (eds): Best Methods for the Analysis of Change. Washington, American Psychological Association, 1991, pp 184-203.
67. Lipman RS: Depression scales derived from the Hopkins Symptom Checklist; in Sartorius N, Ban T (eds): Assessment of Depression. Berlin, Springer, 1986, pp 232-248.
68. Papakostas GI, Ostergaard SD, Iovieno N: The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015; 76: 456-466.
69. Bech P: Is the antidepressive effect of secondgeneration antidepressants a myth? Psychol Med 2010; 40: 181-186.
70. Licht RW, Qvitzau S, Allerup P, Bech P: Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005; 111: 144-149.
71. Bech P, Ban TA: A short historical review of SCNP with special reference to the UKU. Acta Neuropsychiatr 2014; 26: 4-7.
72. Bagby RM, Ryder AG, Schuller DR, Marshall MB: The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004; 161: 2163-2177.
73. Prisciandaro JJ, Tolliver BK: An item response theory evaluation of the young mania rating scale and the Montgomery-Asberg depression rating scale in the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord 2016; 205: 73-80.
74. Ostergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ; STOP-PD Study Group: Measuring psychotic depression. Acta Psychiatr Scand 2014; 129: 211-220.
75. Ostergaard SD, Pedersen CH, Uggerby P, Munk-Jorgensen P, Rothschild AJ, Larsen JI, Gotzsche C, Sondergaard MG, Bille AG, Bolwig TG, Larsen JK, Bech P: Clinical and psychometric validation of the Psychotic Depression Assessment Scale. J Affect Disord 2015; 173: 261-268.
76. Ostergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Leadholm AK, Bech P, Meyers BS: Rating scales measuring the severity of psychotic depression. Acta Psychiatr Scand 2015; 132: 335-344.
77. Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812.
78. Ostergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Vermeulen T, Bech P, Meyers BS: Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). J Affect Disord 2016; 190: 111-114.
79. Ostergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ; STOP-PD Study Group: Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord 2014; 160: 68-73.
80. Ostergaard SD, Lemming OM, Mors O, Correll CU, Bech P: PANSS-6: a brief rating scale for the measurement of severity in schizophrenia. Acta Psychiatr Scand 2016; 133: 436-444.
81. Bech P, Wilson P, Wessel T, Lunde M, Fava M: A validation analysis of two self-reported HAM-D6 versions. Acta Psychiatr Scand 2009; 119: 298-303.
82. Bech P, Allerup P, Gram LF, Reisby N, Rosenberg R, Jacobsen O, Nagy A: The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand 1981; 63: 290-299.
83. Bech P, Allerup P, Reisby N, Gram LF: Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants. Psychopharmacology (Berl) 1984; 84: 276-281.
84. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ: Factor structure and dimensionality of the two depression scales in STAR ∗ D using level 1 datasets. J Affect Disord 2011; 132: 396-400.
85. Korner A, Lauritzen L, Abelskov K, Gulmann NC, Brodersen AM, Wedervang-Jensen T, Marie Kjeldgaard K: Rating scales for depression in the elderly: external and internal validity. J Clin Psychiatry 2007; 68: 384-389.
86. Bech P, Kajdasz DK, Porsdal V: Dose-response relationship of duloxetine in placebocontrolled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006; 188: 273-280.
87. Bech P, Boyer P, Germain JM, Padmanabhan K, Haudiquet V, Pitrosky B, Tourian KA: HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry 2010; 43: 271-276.